Review
. 2017 Jun;9().
doi: 10.2147/BCTT.S109847.

Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer

Terri P McVeigh 1 Michael J Kerin 1 
Affiliations
  • PMID: 28615971
  •     60 References
  •     24 citations

Abstract

Implementation of the Oncotype DX assay has led to a change in the manner in which chemotherapy is utilized in patients with early stage, estrogen receptor (ER)-positive, node-negative breast cancer; ensuring that patients at highest risk of recurrence are prescribed systemic treatment, while at the same time sparing low-risk patients potential adverse events from therapy unlikely to influence their survival. This test generates a recurrence score between 0 and 100, which correlates with probability of distant disease recurrence. Patients with low-risk recurrence scores (0-17) are unlikely to derive significant survival benefit with adjuvant chemotherapy and hormonal agents derived from using adjuvant hormonal therapy only. Conversely, adjuvant chemotherapy has been shown to significantly improve survival in patients with high-risk recurrence scores (≥31). Trials are ongoing to determine how best to manage patients with recurrence scores in the intermediate range. This review outlines the introduction and impact of Oncotype DX testing on practice; ongoing clinical trials investigating its utility; and challenging clinical scenarios where the absolute recurrence score may require careful interpretation. We also performed a bibliometric analysis of publications on the topics of breast cancer and Oncotype DX as a surrogate marker of acceptability and incorporation of the assay into the management of patients with breast cancer.

Keywords: Oncotype DX; breast cancer; gene expression profiling; personalized medicine; precision medicine.

Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer.
Maureen Cronin, Chithra Sangli, +7 authors, Drew Watson.
Clin Chem, 2007 Apr 28; 53(6). PMID: 17463177
Highly Cited.
Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer.
Peter S Hall, Christopher McCabe, Robert C Stein, David Cameron.
J Natl Cancer Inst, 2011 Dec 06; 104(1). PMID: 22138097
Influence of a 21-Gene Recurrence Score Assay on Chemotherapy Delivery in Breast Cancer.
Charles E Rutter, Xiaopan Yao, +7 authors, Suzanne B Evans.
Clin Breast Cancer, 2015 Oct 21; 16(1). PMID: 26483315
Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?
Steven A Narod, Kelly Metcalfe, +14 authors, Jan Lubinski.
Breast Cancer Res Treat, 2013 Feb 06; 138(1). PMID: 23381743
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Gong Tang, Steven Shak, +6 authors, Norman Wolmark.
Breast Cancer Res Treat, 2011 Jan 12; 127(1). PMID: 21221771    Free PMC article.
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.
Donald A Berry, Constance Cirrincione, +9 authors, Eric P Winer.
JAMA, 2006 Apr 13; 295(14). PMID: 16609087    Free PMC article.
Highly Cited.
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R Peto, +15 authors, K Pritchard.
Lancet, 2011 Dec 14; 379(9814). PMID: 22152853    Free PMC article.
Highly Cited.
Long-term cost-effectiveness of Oncotype DX® versus current clinical practice from a Dutch cost perspective.
Michelle Kip, Helma Monteban, Lotte Steuten.
J Comp Eff Res, 2015 Apr 16; 4(5). PMID: 25872415
Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009.
Michaela A Dinan, Xiaojuan Mi, +3 authors, Lesley H Curtis.
JAMA Oncol, 2015 Jul 17; 1(2). PMID: 26181015
Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
Juhi Asad, Allyson F Jacobson, +7 authors, Paul I Tartter.
Am J Surg, 2008 Sep 24; 196(4). PMID: 18809056
Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
Payal D Shah, Sujata Patil, +3 authors, Mark E Robson.
Cancer, 2016 Feb 10; 122(8). PMID: 26859126
Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer.
Maria Karsten, Michelle Stempel, +2 authors, Tari A King.
Ann Surg Oncol, 2015 Sep 06; 23(2). PMID: 26340863    Free PMC article.
The Nottingham Prognostic Index in primary breast cancer.
M H Galea, R W Blamey, C E Elston, I O Ellis.
Breast Cancer Res Treat, 1992 Jan 01; 22(3). PMID: 1391987
Highly Cited.
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.
Laurel A Habel, Steven Shak, +12 authors, Charles P Quesenberry.
Breast Cancer Res, 2006 Jun 02; 8(3). PMID: 16737553    Free PMC article.
Highly Cited.
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Mitch Dowsett, Jack Cuzick, +11 authors, Steven Shak.
J Clin Oncol, 2010 Mar 10; 28(11). PMID: 20212256
Highly Cited.
The influence of a gene expression profile on breast cancer decisions.
Leonard R Henry, Alexander Stojadinovic, +3 authors, Peter W Soballe.
J Surg Oncol, 2009 Feb 11; 99(6). PMID: 19204954
Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies.
Fiona M Blows, Kristy E Driver, +40 authors, David Huntsman.
PLoS Med, 2010 Jun 04; 7(5). PMID: 20520800    Free PMC article.
Highly Cited.
Barriers to the use of personalized medicine in breast cancer.
Christine B Weldon, Julia R Trosman, +2 authors, Julian C Schink.
J Oncol Pract, 2012 Nov 28; 8(4). PMID: 23180995    Free PMC article.
Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.
Shelly S Lo, Patricia B Mumby, +8 authors, Kathy S Albain.
J Clin Oncol, 2010 Jan 13; 28(10). PMID: 20065191
Highly Cited.
Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer.
Joan Albanell, Christer Svedman, +6 authors, Wolfgang Eiermann.
Eur J Cancer, 2016 Aug 22; 66. PMID: 27544930
Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
Bernard Fisher, Jong-Hyeon Jeong, +5 authors, National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
Lancet, 2004 Sep 08; 364(9437). PMID: 15351193
Women's experiences with genomic testing for breast cancer recurrence risk.
Janice P Tzeng, Deborah Mayer, +5 authors, Noel T Brewer.
Cancer, 2010 Mar 10; 116(8). PMID: 20213682
Chemotherapy benefit for 'ER-positive' breast cancer and contamination of nonluminal subtypes—waiting for TAILORx and RxPONDER.
Z Sun, A Prat, +2 authors, C M Perou.
Ann Oncol, 2014 Oct 31; 26(1). PMID: 25355719    Free PMC article.
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.
A Goldhirsch, W C Wood, +4 authors, Panel members.
Ann Oncol, 2011 Jun 29; 22(8). PMID: 21709140    Free PMC article.
Highly Cited.
Development of the 21-gene assay and its application in clinical practice and clinical trials.
Joseph A Sparano, Soonmyung Paik.
J Clin Oncol, 2008 Feb 09; 26(5). PMID: 18258979
Highly Cited. Review.
Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial.
Judy C Boughey, Linda M McCall, +7 authors, Kelly K Hunt.
Ann Surg, 2014 Sep 10; 260(4). PMID: 25203877    Free PMC article.
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.
Kathy S Albain, William E Barlow, +18 authors, Breast Cancer Intergroup of North America.
Lancet, 2009 Dec 17; 374(9707). PMID: 20004966    Free PMC article.
TAILORx: trial assigning individualized options for treatment (Rx).
Joseph A Sparano.
Clin Breast Cancer, 2006 Nov 10; 7(4). PMID: 17092406
Cost-effectiveness of the 21-gene breast cancer assay in Mexico.
Juan Enrique Bargalló-Rocha, Fernando Lara-Medina, +8 authors, William J Valentine.
Adv Ther, 2015 Mar 06; 32(3). PMID: 25740550
Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer.
Catherine Oakman, Silvia Bessi, +3 authors, Angelo Di Leo.
Breast Cancer Res, 2009 May 14; 11(2). PMID: 19435470    Free PMC article.
Review.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer.
M E Lippman, J C Allegra, +7 authors, R Warren.
N Engl J Med, 1978 Jun 01; 298(22). PMID: 651963
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Dennis C Sgroi, Ivana Sestak, +9 authors, Mitch Dowsett.
Lancet Oncol, 2013 Sep 17; 14(11). PMID: 24035531    Free PMC article.
Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
Hannah Y Wen, Melissa Krystel-Whittemore, +7 authors, Edi Brogi.
Cancer, 2016 Aug 16; 123(1). PMID: 27526056    Free PMC article.
ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY.
Megan C Roberts, Amy Bryson, +4 authors, Stephanie B Wheeler.
Int J Technol Assess Health Care, 2016 Dec 14; 32(5). PMID: 27958190    Free PMC article.
Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.
Banu Arun, Soley Bayraktar, +8 authors, Constance Albarracin.
J Clin Oncol, 2011 Sep 09; 29(28). PMID: 21900106    Free PMC article.
Experiences and attitudes toward risk of recurrence testing in women with breast cancer: a systematic review.
Laura E Leggett, Diane L Lorenzetti, +3 authors, Fiona Clement.
Breast Cancer Res Treat, 2014 Mar 07; 144(3). PMID: 24596049
Systematic Review.
Signatures of mutational processes in human cancer.
Ludmil B Alexandrov, Serena Nik-Zainal, +72 authors, Michael R Stratton.
Nature, 2013 Aug 16; 500(7463). PMID: 23945592    Free PMC article.
Highly Cited.
The value of personalizing medicine: medical oncologists' views on gene expression profiling in breast cancer treatment.
Yvonne Bombard, Linda Rozmovits, +3 authors, Deborah A Marshall.
Oncologist, 2015 Mar 10; 20(4). PMID: 25746345    Free PMC article.
The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.
Sunil R Lakhani, Marc J Van De Vijver, +4 authors, Douglas F Easton.
J Clin Oncol, 2002 May 01; 20(9). PMID: 11981002
Highly Cited.
Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations.
R Lewin, A Sulkes, +11 authors, R Yerushalmi.
Breast Cancer Res Treat, 2016 May 27; 157(3). PMID: 27225387
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.
Lawrence J Solin, Robert Gray, +13 authors, Sunil Badve.
J Natl Cancer Inst, 2013 May 04; 105(10). PMID: 23641039    Free PMC article.
Highly Cited.
Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland.
Lillian Smyth, Geoff Watson, +13 authors, Janice M Walshe.
Breast Cancer Res Treat, 2015 Sep 14; 153(3). PMID: 26364296
21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.
Jagar Jasem, Arya Amini, +4 authors, Peter Kabos.
J Clin Oncol, 2016 Mar 24; 34(17). PMID: 27001563    Free PMC article.
Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
J Loncaster, A Armstrong, +5 authors, N J Bundred.
Eur J Surg Oncol, 2017 Jan 24; 43(5). PMID: 28111076
Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer.
Adam M Brufsky.
Am J Clin Oncol, 2014 May 24; 37(4). PMID: 24853663    Free PMC article.
Systematic Review.
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
E Senkus, S Kyriakides, +6 authors, ESMO Guidelines Committee.
Ann Oncol, 2015 Sep 01; 26 Suppl 5. PMID: 26314782
Highly Cited.
Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.
William D Foulkes, Ingunn M Stefansson, +5 authors, Lars A Akslen.
J Natl Cancer Inst, 2003 Oct 02; 95(19). PMID: 14519755
Highly Cited.
Size surprise? Tumour size, nodal status, and outcome after breast cancer.
W D Foulkes.
Curr Oncol, 2012 Nov 13; 19(5). PMID: 23144568    Free PMC article.
Landscape of somatic mutations in 560 breast cancer whole-genome sequences.
Serena Nik-Zainal, Helen Davies, +85 authors, Michael R Stratton.
Nature, 2016 May 03; 534(7605). PMID: 27135926    Free PMC article.
Highly Cited.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Assessing the impact of neoadjuvant chemotherapy on the management of the breast and axilla in breast cancer.
Terri Patricia McVeigh, Dhafir Al-Azawi, +6 authors, Michael J Kerin.
Clin Breast Cancer, 2013 Oct 26; 14(1). PMID: 24157259
Factors predicting late recurrence for estrogen receptor-positive breast cancer.
Ivana Sestak, Mitch Dowsett, +4 authors, Jack Cuzick.
J Natl Cancer Inst, 2013 Sep 14; 105(19). PMID: 24029245    Free PMC article.
Highly Cited.
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, +14 authors, A L Børresen-Dale.
Proc Natl Acad Sci U S A, 2001 Sep 13; 98(19). PMID: 11553815    Free PMC article.
Highly Cited.
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.
Lori J Goldstein, Robert Gray, +12 authors, Joseph A Sparano.
J Clin Oncol, 2008 Aug 06; 26(25). PMID: 18678838    Free PMC article.
Highly Cited.
Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score.
Ivana Sestak, Jack Cuzick, +8 authors, Michael Gnant.
J Clin Oncol, 2014 Oct 22; 33(8). PMID: 25332252
Highly Cited.
Women's interest in gene expression analysis for breast cancer recurrence risk.
Suzanne C O'Neill, Noel T Brewer, +4 authors, Barbara K Rimer.
J Clin Oncol, 2007 Oct 11; 25(29). PMID: 17925559
The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre.
Terri Patricia McVeigh, Lauren M Hughes, +4 authors, Michael J Kerin.
Eur J Cancer, 2014 Sep 23; 50(16). PMID: 25240289    Free PMC article.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +28 authors, George W Sledge.
N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412349    Free PMC article.
Highly Cited.
Novel Strategies on Personalized Medicine for Breast Cancer Treatment: An Update.
Carmen W H Chan, Bernard M H Law, +2 authors, Mary M Y Waye.
Int J Mol Sci, 2017 Nov 16; 18(11). PMID: 29140300    Free PMC article.
Review.
Biospecimen donation among black and white breast cancer survivors: opportunities to promote precision medicine.
Vanessa B Sheppard, Alejandra Hurtado-de-Mendoza, +10 authors, Mahlet Tadesse.
J Cancer Surviv, 2017 Nov 18; 12(1). PMID: 29147853
Quantitative or qualitative transcriptional diagnostic signatures? A case study for colorectal cancer.
Qingzhou Guan, Haidan Yan, +10 authors, Zheng Guo.
BMC Genomics, 2018 Jan 31; 19(1). PMID: 29378509    Free PMC article.
Addressing the challenges of applying precision oncology.
Seung Ho Shin, Ann M Bode, Zigang Dong.
NPJ Precis Oncol, 2018 Jun 07; 1(1). PMID: 29872710    Free PMC article.
Review.
Advances in Precision Health and Emerging Diagnostics for Women.
Megan B Fitzpatrick, Avnesh S Thakor.
J Clin Med, 2019 Sep 25; 8(10). PMID: 31547515    Free PMC article.
Review.
Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li-Fraumeni syndrome).
Vanessa Petry, Renata Colombo Bonadio, +6 authors, Maria Del Pilar Estevez-Diz.
Fam Cancer, 2019 Nov 22; 19(1). PMID: 31748977
Review.
MetaGxData: Clinically Annotated Breast, Ovarian and Pancreatic Cancer Datasets and their Use in Generating a Multi-Cancer Gene Signature.
Deena M A Gendoo, Michael Zon, +5 authors, Benjamin Haibe-Kains.
Sci Rep, 2019 Jun 21; 9(1). PMID: 31217513    Free PMC article.
The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials.
Terri Patricia McVeigh, Raghav Sundar, +6 authors, Angela J George.
Eur J Cancer, 2018 Apr 04; 95. PMID: 29614442    Free PMC article.
Online accounts of gene expression profiling in early-stage breast cancer: Interpreting genomic testing for chemotherapy decision making.
Emily Ross, Julia Swallow, Anne Kerr, Sarah Cunningham-Burley.
Health Expect, 2018 Nov 06; 22(1). PMID: 30387238    Free PMC article.
Patterns of Care and Efficacy of Chemotherapy and Radiotherapy in Skin-Involved Breast Cancers of All Sizes.
Alina M Mateo, Anna M Mazor, +7 authors, Richard J Bleicher.
Clin Breast Cancer, 2019 Mar 16; 19(4). PMID: 30871966    Free PMC article.
Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies.
Mauricio A Medina, Goldie Oza, +4 authors, Jose Tapia Ramirez.
Int J Environ Res Public Health, 2020 Apr 05; 17(6). PMID: 32245065    Free PMC article.
Review.
Single-center versus multi-center data sets for molecular prognostic modeling: a simulation study.
Daniel Samaga, Roman Hornung, +5 authors, Kristian Unger.
Radiat Oncol, 2020 May 16; 15(1). PMID: 32410693    Free PMC article.
RDGN-based predictive model for the prognosis of breast cancer.
Bing Dong, Ming Yi, +2 authors, Kongming Wu.
Exp Hematol Oncol, 2020 Jun 19; 9. PMID: 32550045    Free PMC article.
Oncologist Confidence in Genomic Testing and Implications for Using Multimarker Tumor Panel Tests in Practice.
Janet S de Moor, Stacy W Gray, +2 authors, Andrew N Freedman.
JCO Precis Oncol, 2020 Sep 15; 4. PMID: 32923869    Free PMC article.
LobSig is a multigene predictor of outcome in invasive lobular carcinoma.
Amy E McCart Reed, Samir Lal, +18 authors, Peter T Simpson.
NPJ Breast Cancer, 2019 Jul 03; 5. PMID: 31263747    Free PMC article.
A Pre-operative Nomogram for Prediction of Lymph Node Metastasis in Bladder Urothelial Carcinoma.
Xiaofan Lu, Yang Wang, +9 authors, Fangrong Yan.
Front Oncol, 2019 Jul 12; 9. PMID: 31293963    Free PMC article.
The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center.
Stephane Thibodeau, Ioannis A Voutsadakis.
Eur J Breast Health, 2019 Jul 18; 15(3). PMID: 31312792    Free PMC article.
Harmonization of Molecular Testing for Non-Small Cell Lung Cancer: Emphasis on PD-L1.
Evgeny N Imyanitov, Alexandr O Ivantsov, Ilya V Tsimafeyeu.
Front Oncol, 2020 Oct 27; 10. PMID: 33102215    Free PMC article.
Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016.
Thomas M Schwedhelm, Judy R Rees, +4 authors, Erika L Moen.
BMC Cancer, 2020 Sep 05; 20(1). PMID: 32883270    Free PMC article.
Cole Relaxation Frequency as a Prognostic Parameter for Breast Cancer.
William D Gregory, Shahila Mehboob Christie, +3 authors, Wendy Mikkelson.
J Patient Cent Res Rev, 2020 Nov 10; 7(4). PMID: 33163555    Free PMC article.
An Epithelial-Mesenchymal Transition (EMT) Preoperative Nomogram for Prediction of Lymph Node Metastasis in Bladder Cancer (BLCA).
Rui Cao, Bo Ma, +3 authors, Lushun Yuan.
Dis Markers, 2020 Nov 19; 2020. PMID: 33204364    Free PMC article.
Predictability of 21-Gene Recurrence Score Assay by Using Pathological and Immunohistochemical Parameters in Breast Cancer.
Abdulmohsen Alkushi, Ahmad Omair, +2 authors, Omalkhair Abualkhair.
Breast Cancer (Auckl), 2020 Dec 22; 14. PMID: 33343196    Free PMC article.
Invasive lobular carcinoma of the breast: the increasing importance of this special subtype.
Amy E McCart Reed, Lauren Kalinowski, Peter T Simpson, Sunil R Lakhani.
Breast Cancer Res, 2021 Jan 09; 23(1). PMID: 33413533    Free PMC article.
Review.
Background Parenchymal Enhancement on Breast MRI as a Prognostic Surrogate: Correlation With Breast Cancer Oncotype Dx Score.
Michelle Zhang, Meredith Sadinski, +5 authors, Elizabeth J Sutton.
Front Oncol, 2021 Feb 23; 10. PMID: 33614481    Free PMC article.